A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorTakeda
About this trial
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of brigatinib among adult participants who have been administered brigatinib as per the approved indications.
Eligibility criteria
Qualifiers
With ALK-positive advanced or metastatic NSCLC.
Who initiate brigatinib for the first time.
Disqualifiers
Treated with brigatinib outside of the locally approved label in Korea.
Whom brigatinib is contraindicated as per product label.
Participating in other clinical trials of NSCLC treatment.
Trial design
Treatments tested in this trial
- No Intervention
Treatment groups
257 Participants
are divided into 1 treatment groupLocations
1Pusan National University Hospital49241, Busan South Korea
Sponsors and collaborators
Takeda
Lead sponsor
Source ClinicalTrials.gov